Abstract
Introduction: Despite recent advances in diagnosis, prognostication, and treatment options, chronic lymphocytic leukemia (CLL) is still a largely incurable disease. New concepts on diagnosis, staging, treatment, and follow-up on CLL have been incorporated throughout recent years. The lack of regional consensus guidelines has led to varying practices in the management of patients with CLL in the region. This manuscript aims to reach a consensus among expert hematologists regarding the definitions, classifications, and related practices of CLL. The experts developed a set of statements utilizing their personal experience together with the current literature on CLL management. This consensus aims to provide guidance for healthcare professionals involved in the management of CLL and serves as a step in developing regional guidelines. Methods: Eight experts responded to 50 statements regarding the diagnosis, staging, treatment, and prognosis of CLL with three potential answering alternatives ranging between agree, disagree, and abstain. This consensus adopted a modified Delphi consensus methodology. A consensus was reached when at least 75% of the agreement to the answer was reached. This manuscript presents the scientific insights of the participating attendees, panel discussions, and the supporting literature review. Results: Of the 50 statements, a consensus was reached on almost all statements. Statements covered CLL-related topics, including diagnostic evaluation, staging, risk assessment, different patient profiles, prognostic evaluation, treatment decisions, therapy sequences, response evaluation, complications, and CLL during the COVID-19 pandemic. Conclusion: In recent years, CLL management has progressed significantly, with many diagnostic tests and several novel treatments becoming available. This consensus gathers decades of consolidated principles, novel research, and promising prospects for the management of this disease.
Journal Section:
Interdisciplinary Perspectives in Hematology
References
1.
Swerdlow SH, Harris NL, Campo E, Harris NL, Jaffe ES, Pileri SA, et al. WHO classification of tumours of haematopoietic and lymphoid tissues, revised. 4th ed. Lyon, France: International Agency for Research on Cancer; 2017.
2.
Abrisqueta P, Pereira A, Rozman C, Aymerich M, Giné E, Moreno C, et al. Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the hospital clinic of barcelona experience. Blood. 2009;114(10):2044–50.
3.
Mukkamalla SKR, Taneja D, Malipeddi D, Master SR. Chronic lymphocytic leukemia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2021 Oct 1.
4.
GLOBOCAN; Global Cancer observatory. In: International Agency for Research on Cancer. GLOBOCAN; 2019.
5.
Ruchlemer R, Polliack A. Geography, ethnicity and “roots” in chronic lymphocytic leukemia. Leuk Lymphoma. 2013;54(6):1142–50.
6.
Institute of Medicine (US) Committee on Quality of Health Care in America, Kohn LT, Corrigan JM, Donaldson MS. To Err is human: Building a safer health system. Washington (DC): National Academies Press (US); 2000.
7.
Gulf Center for Cancer Control and Prevention. GCCCP: ten-year Cancer incidence among nationals of the GCC states 1998–2007; 2011.
8.
Howard DR, Munir T, McParland L, Rawstron AC, Milligan D, Schuh A, et al. Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL. Leukemia. 2017;31(11):2416–25.
9.
Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J, et al. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015;526(7574):525–30.
10.
Rozovski U, Hazan-Halevy I, Keating MJ, Estrov Z. Personalized medicine in CLL: current status and future perspectives. Cancer Lett. 2014;352(1):4–14.
11.
Eubank BH, Mohtadi NG, Lafave MR, Wiley JP, Bois AJ, Boorman RS, et al. Using the modified Delphi method to establish clinical consensus for the diagnosis and treatment of patients with rotator cuff pathology. BMC Med Res Methodol. 2016;16:56.
12.
Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019–32.
13.
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–60.
14.
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international Workshop on chronic lymphocytic leukemia updating the national cancer institute-working group 1996 guidelines. Blood. 2008;111(12):5446–56.
15.
Wierda WG, Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis CB, et al. NCCN guidelines insights: chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2017. J Natl Compr Canc Netw. 2017;15(3):293–311.
16.
Boyd SD, Natkunam Y, Allen JR, Warnke RA. Selective immunophenotyping for diagnosis of B-cell neoplasms: immunohistochemistry and flow cytometry strategies and results. Appl Immunohistochem Mol Morphol. 2013;21(2):116–31.
17.
Matutes E, Owusu-Ankomah K, Morilla R, Garcia Marco J, Houlihan A, Que TH, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia. 1994;8(10):1640–5.
18.
Rawstron AC, Kreuzer KA, Soosapilla A, Spacek M, Stehlikova O, Gambell P, et al. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: an European research initiative on CLL (ERIC) & European society for clinical cell analysis (ESCCA) harmonisation project. Cytometry B Clin Cytom. 2018;94(1):121–8.
19.
Palumbo GA, Parrinello N, Fargione G, Cardillo K, Chiarenza A, Berretta S, et al. CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia. Leuk Res. 2009;33(9):1212–6.
20.
El-Din Fouad NB, Ibrahim NY, Abdel Aziz RS, Ibrahim SK. CD200 expression in diagnostic and prognostic assessment of mature B-cell lymphophoproliferative neoplasms. Asian Pac J Cancer Prev. 2018;19(12):3383–92.
21.
Yoshino T, Tanaka T, Sato Y. Differential diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma and other indolent lymphomas, including mantle cell lymphoma. J Clin Exp Hematop. 2020;60(4):124–9.
22.
O’Malley DP, Lee JP, Bellizzi AM. Expression of LEF1 in mantle cell lymphoma. Ann Diagn Pathol. 2017;26:57–9.
23.
Menter T, Dirnhofer S, Tzankov A. LEF1: a highly specific marker for the diagnosis of chronic lymphocytic B cell leukaemia/small lymphocytic B cell lymphoma. J Clin Pathol. 2015;68(6):473–8.
24.
Menter T, Trivedi P, Ahmad R, Flora R, Dirnhofer S, Tzankov A, et al. Diagnostic utility of lymphoid enhancer binding factor 1 immunohistochemistry in small B-cell lymphomas. Am J Clin Pathol. 2017;147(3):292–300.
25.
Quinquenel A, Aurran-Schleinitz T, Clavert A, Cymbalista F, Dartigeas C, Davi F, et al. Diagnosis and treatment of chronic lymphocytic leukemia: recommendations of the French CLL study group (FILO). Hemasphere. 2020;4(5):e473.
26.
Strati P, Shanafelt TD. Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification. Blood. 2015;126(4):454–62.
27.
Marti GE, Rawstron AC, Ghia P, Hillmen P, Houlston RS, Kay N, et al. Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol. 2005;130(3):325–32.
28.
Shanafelt TD, Ghia P, Lanasa MC, Landgren O, Rawstron AC. Monoclonal B-cell lymphocytosis (MBL): biology, natural history, and clinical management. Leukemia. 2010;24(3):512–20.
29.
Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46(2):219–34.
30.
Rai KR, Keating JR. Clinical staging and other prognostic features. In: Kufe DW, Weichselbaum RR, Raphael EP, Bast RC, Gansler TS, Holland JF, et al. , editors. Holland-frei cancer medicine. 6th ed. Hamilton (ON): BC Decker; 2003.
31.
Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48(1):198–206.
32.
Hallek M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019;94(11):1266–87.
33.
International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17(6):779–90.
34.
Molica S, Shanafelt TD, Giannarelli D, Gentile M, Mirabelli R, Cutrona G, et al. The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: independent validation in a prospective cohort of early-stage patients. Am J Hematol. 2016;91(11):1090–5.
35.
Condoluci A, Terzi di Bergamo L, Langerbeins P, Hoechstetter MA, Herling CD, De Paoli L, et al. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood. 2020;135(21):1859–69.
36.
Diehl LF, Ketchum LH. Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol. 1998;25(1):80–97.
37.
Parikh SA, Leis JF, Chaffee KG, Call TG, Hanson CA, Ding W, et al. Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: natural history, clinical correlates, and outcomes. Cancer. 2015;121(17):2883–91.
38.
Shephard EA, Neal RD, Rose PW, Walter FM, Hamilton W. Symptoms of adult chronic and acute leukaemia before diagnosis: large primary care case-control studies using electronic records. Br J Gen Pract. 2016;66(644):e182–8.
39.
Johnsen AT, Tholstrup D, Petersen MA, Pedersen L, Groenvold M. Health related quality of life in a nationally representative sample of haematological patients. Eur J Haematol. 2009;83(2):139–48.
40.
Tresckow JV, Eichhorst B, Bahlo J, Hallek M. The treatment of chronic lymphatic leukemia. Dtsch Arztebl Int. 2019;116(4):41–6.
41.
John C. CT scans in response and follow-up assessment of CLL: can we eliminate their use?The Hematologist. 2011;8(2).
42.
Eichhorst BF, Fischer K, Fink AM, Elter T, Wendtner CM, Goede V, et al. Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis. Blood. 2011;117(6):1817–21.
43.
Armitage JO. Staging non-Hodgkin lymphoma. CA Cancer J Clin. 2005;55(6):368–76.
44.
Muntañola A, Bosch F, Arguis P, Arellano-Rodrigo E, Ayuso C, Giné E, et al. Abdominal computed tomography predicts progression in patients with Rai stage 0 chronic lymphocytic leukemia. J Clin Oncol. 2007;25(12):1576–80.
45.
Campo E, Cymbalista F, Ghia P, Jäger U, Pospisilova S, Rosenquist R, et al. TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics. Haematologica. 2018;103(12):1956–68.
46.
Pospisilova S, Gonzalez D, Malcikova J, Trbusek M, Rossi D, Kater AP, et al. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia. 2012;26(7):1458–61.
47.
Rigolin GM, Saccenti E, Bassi C, Lupini L, Quaglia FM, Cavallari M, et al. Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations. J Hematol Oncol. 2016;9(1):88.
48.
Stamatopoulos B, Timbs A, Bruce D, Smith T, Clifford R, Robbe P, et al. Targeted deep sequencing reveals clinically relevant subclonal IgHV rearrangements in chronic lymphocytic leukemia. Leukemia. 2017;31(4):837–45.
49.
Lin KI, Tam CS, Keating MJ, Wierda WG, O’Brien S, Lerner S, et al. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. Blood. 2009;113(14):3168–71.
50.
Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17(7):928–42.
51.
Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, et al. Genomic aberrations, and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910–6.
52.
Hus I, Roliński J. Current concepts in diagnosis and treatment of chronic lymphocytic leukemia. Contemp Oncol. 2015;19(5):361–7.
53.
Sellner L, Denzinger S, Dietrich S, Glimm H, Merkel O, Dreger P, et al. What do we do with chronic lymphocytic leukemia with 17p deletion?Curr Hematol Malig Rep. 2013;8(1):81–90.
54.
Putowski M, Podgórniak M, Piróg M, Knap J, Zaleska J, Purkot J, et al. Prognostic impact of NOTCH1, MYD88, and SF3B1 mutations in Polish patients with chronic lymphocytic leukemia. Pol Arch Intern Med. 2017;127(4):238–44.
55.
Parikh SA, Strati P, Tsang M, West CP, Shanafelt TD. Should IGHV status and FISH testing is performed in all CLL patients at diagnosis? A systematic review and meta-analysis. Blood. 2016;127(14):1752–60.
56.
Shanafelt T. Treatment of older patients with chronic lymphocytic leukemia: key questions and current answers. Hematology. 2013;2013(1):158–67.
57.
Bellera CA, Rainfray M, Mathoulin-Pélissier S, Mertens C, Delva F, Fonck M, et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol. 2012;23(8):2166–72.
58.
Wanchoo R, Bernabe Ramirez C, Barrientos J, Jhaveri KD. Renal involvement in chronic lymphocytic leukemia. Clin Kidney J. 2018;11(5):670–80.
59.
Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, Rifai AH, et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the cumulative illness rating scale. Psychiatry Res. 1992;41(3):237–48.
60.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.
61.
Fresa A, Autore F, Galli E, Tomasso A, Stirparo L, Innocenti I, et al. Treatment options for elderly/unfit patients with chronic lymphocytic leukemia in the era of targeted drugs: a comprehensive review. J Clin Med. 2021;10(21):5104.
62.
Mattsson A, Sylvan SE, Asklid A, Wiggh J, Winqvist M, Lundin J, et al. Risk-adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real-world report on 141 consecutive Swedish patients. Br J Haematol. 2020;191(3):426–32.
63.
de Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity. a critical review of available methods. J Clin Epidemiol. 2003;56(3):221–9.
64.
Gordon MJ, Kaempf A, Sitlinger A, Shouse G, Mei M, Brander DM, et al. The chronic lymphocytic leukemia comorbidity index (CLL-CI): a three-factor comorbidity model. Clin Cancer Res. 2021;27(17):4814–24.
65.
Stauder R, Eichhorst B, Hamaker ME, Kaplanov K, Morrison VA, Österborg A, et al. Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international society of geriatric oncology (SIOG) task force. Ann Oncol. 2017;28(2):218–27.
66.
Strati P, Nasr SH, Leung N, Hanson CA, Chaffee KG, Schwager SM, et al. Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience. Haematologica. 2015;100(9):1180–8.
67.
Stephens JM, Gramegna P, Laskin B, Botteman MF, Pashos CL. Chronic lymphocytic leukemia: economic burden and quality of life: literature review. Am J Ther. 2005;12(5):460–6.
68.
Banerji V, Aw A, Robinson S, Doucette S, Christofides A, Sehn LH. Bruton tyrosine kinase inhibitors for the frontline treatment of chronic lymphocytic leukemia. Curr Oncol. 2020;27(6):e645–55.
69.
Waweru C, Kaur S, Sharma S, Mishra N. Health-related quality of life and economic burden of chronic lymphocytic leukemia in the era of novel targeted agents. Curr Med Res Opin. 2020;36(9):1481–95.
70.
Mansfield C, Masaquel A, Sutphin J, Weiss E, Gutierrez M, Wilson J, et al. Patients’ priorities in selecting chronic lymphocytic leukemia treatments. Blood Adv. 2017;1(24):2176–85.
71.
Spanish Cooperative Group Pethema. Treatment of chronic lymphocytic leukemia: a preliminary report of Spanish (pethema) trials. Leuk Lymphoma. 1991;5(Suppl 1):89–91.
72.
Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists’ Collaborative Group. J Natl Cancer Inst, 1999. 91(10):861–8.
73.
Langerbeins P, Bahlo J, Rhein C, Gerwin H, Cramer P, Fürstenau M, et al. Ibrutinib versus placebo in patients with asymptomatic, treatment-naïve early stage CLL: primary endpoint results of the phase 3 double-blind randomized CLL12 trial. Hematol Oncol. 2019;37(S2):38–40.
74.
Da Cunha-Bang C, Agius R, Kater AP, Levin MD, Österborg A, Mattsson M, et al. PreVent-ACaLL Short-term combined acalabrutinib and venetoclax treatment of newly diagnosed patients with CLL at high risk of infection and/or early treatment, who do not fulfil IWCLL treatment criteria for treatment. A randomized study with extensive immune phenotyping. Blood. 2019;134(Supplement_1):4304.
75.
Awan FT, Al-Sawaf O, Fischer K, Woyach JA. Current perspectives on therapy for chronic lymphocytic leukemia. Am Soc Clin Oncol Educ Book. 2020(40):320–9.
76.
National comprehensive cancer network clinical (NCCN) practice guidelines in oncology. Chronic lymphocytic leukemia/small cell lymphoma; 2023. Available from: https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf.
77.
Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395(10232):1278–91.
78.
Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, et al. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. Leukemia. 2022;36(4):1171–5.
79.
Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Kamdar MK, et al. Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: elevate-TN four-year follow up. J Clin Oncol. 2021;39(15_Suppl l):7509.
80.
Barr PM, Robak T, Owen C, Tedeschi A, Bairey O, Bartlett NL, et al. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica. 2018;103(9):1502–10.
81.
Al-Sawaf O, Zhang C, Tandon M, Sinha A, Fink AM, Robrecht S, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020;21(9):1188–200.
82.
Tam CS, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Jurczak W, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022;23(8):1031–43.
83.
Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225–36.
84.
Farooqui MZ, Valdez J, Martyr S, Aue G, Saba N, Niemann CU, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol. 2015;16(2):169–76.
85.
Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–23.
86.
Jones JA, Mato AR, Wierda WG, Davids MS, Choi M, Cheson BD, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19(1):65–75.
87.
Moreno C. Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy. Hematology. 2020;2020(1):33–40.
88.
Smolewski P, Robak T. Current treatment of refractory/relapsed chronic lymphocytic leukemia: a focus on novel drugs. Acta Haematol. 2021;144(4):365–79.
89.
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pirtobrutinib-relapsed-or-refractory-mantle-cell-lymphoma.
90.
AstraZeneca. US FDA approves AstraZeneca’s calquence (acalabrutinib) for adult patients with previously-treated mantle cell lymphoma; 2017.
91.
Byrd JC, Wierda WG, Schuh A, Devereux S, Chaves JM, Brown JR, et al. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood. 2020;135(15):1204–13.
92.
Abbas HA, Wierda WG. Acalabrutinib: a selective bruton tyrosine kinase inhibitor for the treatment of B-cell malignancies. Front Oncol. 2021;11:668162.
93.
Puła B, Gołos A, Górniak P, Jamroziak K. Overcoming ibrutinib resistance in chronic lymphocytic leukemia. Cancers. 2019;11(12):1834.
94.
Byrd JC, Woyach JA, Furman RR, Martin P, O’Brien S, Brown JR, et al. Acalabrutinib in treatment-naive chronic lymphocytic leukemia. Blood. 2021;137(24):3327–38.
95.
Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–37.
96.
Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517–28.
97.
Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17(6):768–78.
98.
Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D’Rozario J, Assouline S, et al. Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107–20.
99.
Bewarder M, Stilgenbauer S, Thurner L, Kaddu-Mulindwa D. Current treatment options in CLL. Cancers. 2021;13(10):2468.
100.
Seymour JF, Ma S, Brander DM, Choi MY, Barrientos J, Davids MS, et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol. 2017;18(2):230–40.
101.
Eichhorst B, Hallek M, Dreyling M; ESMO Guidelines Working Group. Chronic lymphocytic leukemia: ESMO minimum clinical recommendations for diagnosis, treatment, and follow-up. Ann Oncol. 2009;20(Suppl 4):102–4. iv102–iv104
102.
Kovacs G, Robrecht S, Fink AM, Bahlo J, Cramer P, von Tresckow J, et al. Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of two-phase III studies of the German CLL study group. J Clin Oncol. 2016;34(31):3758–65.
103.
Strati P, Keating MJ, O’Brien SM, Burger J, Ferrajoli A, Jain N, et al. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood. 2014;123(24):3727–32.
104.
Thompson PA, Peterson CB, Strati P, Jorgensen J, Keating MJ, O’Brien SM, et al. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia. 2018;32(11):2388–98.
105.
Cheson BD, Mato AR, The evolving use of minimal residual disease (MRD) assessment in chronic lymphocytic leukemia: Q&A. Clin Adv Hematol Oncol. 2020;18 Suppl 10(6):1–20.
106.
Lew TE, Anderson MA, Lin VS, Handunnetti SM, Came NA, Blombery P, et al. Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months. Blood Adv. 2020;4(1):165–73.
107.
Uchiyama T, Yokoyama A, Aoki S. Measurable residual disease in the treatment of chronic lymphocytic leukemia. J Clin Exp Hematop. 2020;60(4):138–45.
108.
Agency EM. Guideline on the use of minimal residual disease as an endpoint in chronic lymphocytic leukemia studies. London: European Medicines Agency (EMA); 2014.
109.
Del Giudice I, Raponi S, Della Starza I, De Propris MS, Cavalli M, De Novi LA, et al. Minimal residual disease in chronic lymphocytic leukemia: a new goal?Front Oncol. 2019;9:689.
110.
Wierda WG, Rawstron A, Cymbalista F, Badoux X, Rossi D, Brown JR, et al. Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. Leukemia. 2021;35(11):3059–72.
111.
Böttcher S, Hallek M, Ritgen M, Kneba M. The role of minimal residual disease measurements in the therapy for CLL: is it ready for prime time?Hematol Oncol Clin North Am. 2013;27(2):267–88.
112.
Herth I, Dietrich S, Benner A, Hegenbart U, Rieger M, Stadtherr P, et al. The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison. Ann Oncol. 2014;25(1):200–6.
113.
Gribben JG. How and when I do allogeneic transplant in CLL. Blood. 2018;132(1):31–9.
114.
Zhang X, Chen J, Han MZ, Huang H, Jiang EL, Jiang M, et al. The consensus from the Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. J Hematol Oncol. 2021;14(1):145.
115.
Dreger P, Corradini P, Kimby E, Michallet M, Milligan D, Schetelig J, et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia. 2007;21(1):12–7.
116.
Zent CS, Ding W, Schwager SM, Reinalda MS, Hoyer JD, Jelinek DF, et al. The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. Br J Haematol. 2008;141(5):615–21.
117.
Zent CS, Ding W, Reinalda MS, Schwager SM, Hoyer JD, Bowen DA, et al. Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis. Leuk Lymphoma. 2009;50(8):1261–8.
118.
Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, et al. Recommendations for the use of WBC growth factors: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2015;33(28):3199–212.
119.
Leukemia and Lymphoma Society. Complications of CLL or CLL treatment. In: Steven Coutre M, editor. Chronic lymphocytic leukemia; 2021.
120.
Spiekermann K, Roesler J, Emmendoerffer A, Elsner J, Welte K. Functional features of neutrophils induced by G-CSF and GM-CSF treatment: differential effects and clinical implications. Leukemia. 1997;11(4):466–78.
121.
Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G. Filgrastim (r-metHuG-CSF): the first 10 years. Blood. 1996;88(6):1907–29.
122.
Laurenti L, Vannata B, Innocenti I, Autore F, Santini F, Sica S, et al. The use of monoclonal antibodies in the treatment of autoimmune complications of chronic lymphocytic leukemia. Mediterr J Hematol Infect Dis. 2013;5(1):e2013027.
123.
Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, et al. American society of Hematology/American society of clinical oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood. 2010;116(20):4045–59.
124.
Besa EC. Use of intravenous immunoglobulin in chronic lymphocytic leukemia. Am J Med. 1984;76(3a):209–18.
125.
Ferrer G. Immunoglobulin replacement therapy targeting the BCR in chronic lymphocytic leukemia. EBioMedicine. 2018;36:7–8.
126.
Federmann B, Mueller MR, Steinhilber J, Horger MS, Fend F. Diagnosis of Richter transformation in chronic lymphocytic leukemia: histology tips the scales. Ann Hematol. 2018;97(10):1859–68.
127.
Bruzzi JF, Macapinlac H, Tsimberidou AM, Truong MT, Keating MJ, Marom EM, et al. Detection of Richter’s transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med. 2006;47(8):1267–73.
128.
Mauro FR, Chauvie S, Paoloni F, Biggi A, Cimino G, Rago A, et al. Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease. Leukemia. 2015;29(6):1360–5.
129.
Musanhu E, Sharma RK, Attygalle A, Wotherspoon A, Chau I, Cunningham D, et al. Chronic lymphocytic leukaemia and Richter’s transformation: multimodal review and new imaging paradigms. Clin Radiol. 2021;76(11):789–800.
130.
Agbay RL, Jain N, Loghavi S, Medeiros LJ, Khoury JD. Histologic transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol. 2016;91(10):1036–43.
131.
Parikh SA, Kay NE, Shanafelt TD. How we treat Richter syndrome. Blood. 2014;123(11):1647–57.
132.
Rossi D, Spina V, Gaidano G. Biology and treatment of Richter syndrome. Blood. 2018;131(25):2761–72.
133.
Kuy S, Gupta R, Correa R, Tsai R, Vohra S. Best practices for a Covid-19 preparedness plan for health systems. NEJM Catalyst Innov Care Deliv. 2020;1(2).
134.
American Medical Association. AMA digital health care 2016 & 2019 study findings; 2019.
135.
Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American society of clinical oncology and infectious diseases society of America clinical practice guideline update. J Clin Oncol. 2018;36(14):1443–53.
136.
EMA. Venclyxto (venetoclax) EPAR: an overview of Venclyxto and why it is authorized in the EU; 2018.
137.
Anderson MA, Deng J, Seymour JF, Tam C, Kim SY, Fein J, et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood. 2016;127(25):3215–24.
138.
Di Ciaccio P, McCaughan G, Trotman J, Ho PJ, Cheah CY, Gangatharan S, et al. Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic. Intern Med J. 2020;50(6):667–79.
139.
Maschmeyer G, De Greef J, Mellinghoff SC, Nosari A, Thiebaut-Bertrand A, Bergeron A, et al. Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL). Leukemia. 2019;33(4):844–62.
140.
Coutre S, Byrd JC, Hillmen P, Barrientos JC, Barr PM, Devereux S, et al. Integrated and long-term safety analysis of ibrutinib in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Blood. 2016;128(22):4383.
141.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62.
142.
American Society Of Hematology. COVID-19 and CLL: frequently asked questions; 2021. (cited 2022); Available from: https://www.hematology.org/covid-19/covid-19-and-cll.
143.
Alexander KE, Tong PL, Macartney K, Beresford R, Sheppeard V, Gupta M. Live zoster vaccination in an immunocompromised patient leading to death secondary to disseminated varicella zoster virus infection. Vaccine. 2018;36(27):3890–3.
144.
Benjamini O, Rokach L, Itchaki G, Braester A, Shvidel L, Goldschmidt N, et al. Safety and efficacy of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia. Haematologica; 2021;107(3):625–34.
145.
Morawska M. Reasons, and consequences of COVID-19 vaccine failure in patients with chronic lymphocytic leukemia. Eur J Haematol. 2022;108(2):91–8.
146.
Mato AR, Roeker LE, Lamanna N, Allan JN, Leslie L, Pagel JM, et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020;136(10):1134–43.
147.
Roeker LE, Knorr DA, Thompson MC, Nivar M, Lebowitz S, Peters N, et al. COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia. Leukemia. 2021;35(9):2703–5.
148.
Herzog Tzarfati K, Gutwein O, Apel A, Rahimi-Levene N, Sadovnik M, Harel L, et al. BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies. Am J Hematol. 2021;96(10):1195–203.
149.
Petracci F, Ghai C, Pangilinan A, Suarez LA, Uehara R, Ghosn M. Use of real-world evidence for oncology clinical decision making in emerging economies. Future Oncol. 2021;17(22):2951–60.
150.
Dearden C, Wade R, Else M, Richards S, Milligan D, Hamblin T, et al. The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood. 2008;111(4):1820–6.
151.
Mauro FR, Foa R, Cerretti R, Giannarelli D, Coluzzi S, Mandelli F, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood. 2000;95(9):2786–92.
© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.
